What is SpliSense?
Founded in 2016, SpliSense operates at the intersection of molecular biology and clinical medicine. The company specializes in the development of transformative mRNA-altering treatments designed to address the root causes of genetic pulmonary diseases. By leveraging advanced RNA-modulating technologies, SpliSense aims to provide therapeutic solutions for patients suffering from conditions that have historically lacked effective interventions. Its market position is defined by a robust pipeline and a strategic focus on high-impact genetic targets, distinguishing it within the competitive landscape of biotechnology firms focused on rare and chronic respiratory disorders.
How much funding has SpliSense raised?
SpliSense has raised a total of $41.5M across 2 funding rounds:
Series B
$28.5M
Other Financing Round
$13M
Series B (2021): $28.5M with participation from Israel Biotech Fund, Biotel Limited, Cystic Fibrosis Foundation, Integra Holdings, and OrbiMed
Other Financing Round (2026): $13M led by Cystic Fibrosis Foundation
Key Investors in SpliSense
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with a focus on multi-stage development.
Integra Holdings
Integra Holdings serves as an exclusive gateway for investment in early-stage life science research and technologies, facilitating the transition of academic innovations into the business realm.
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a non-profit organization dedicated to providing the means to cure cystic fibrosis and ensuring that those living with the condition lead long and productive lives.
What's next for SpliSense?
With the successful closure of this latest financing round, SpliSense is expected to prioritize the expansion of its clinical pipeline and the optimization of its mRNA-altering delivery mechanisms. The strategic focus will likely shift toward advancing lead candidates through critical regulatory milestones and expanding its research footprint. As the company matures, the integration of this capital will be pivotal in scaling its operational capabilities and fostering potential partnerships that could enhance the commercial viability of its therapeutic assets. Investors will be closely monitoring the company's progress in translating its preclinical successes into tangible clinical outcomes, which will be essential for long-term value creation in the biopharmaceutical sector.
See full SpliSense company page
